Cabozantinib: A Novel Multiple Tyrosine-Kinase Targeted Agent in Anti-Angiogenic Therapy

Strategic Insights -

Recent research on oncology has highlighted the potential of cabozantinib, a novel multiple tyrosine-kinase targeted agent, in anti-angiogenic therapy for the treatment of various solid tumors. The study, conducted by researchers at the College of Pharmacy, revealed that cabozantinib has shown efficacy in inhibiting angiogenesis and cancer growth in preclinical and clinical studies. The research identified cabozantinib as a promising therapeutic option for the treatment of multiple solid tumors, including breast cancer, castration-resistant prostate cancer, renal cell carcinoma, and others.

Key Takeaways:

  • Cabozantinib is a novel multiple tyrosine-kinase targeted agent that inhibits both VEGFR2 and c-Met simultaneously, thereby preventing angiogenesis and cancer growth.
  • The drug was approved by the US FDA on November 29, 2012, for the treatment of Medullary Thyroid Cancer (MTC).
  • Cabozantinib has shown efficacy in preclinical and clinical studies, indicating its potential as a therapeutic agent for the treatment of various solid tumors.
  • The research identified cabozantinib as a promising therapeutic option for the treatment of breast cancer, castration-resistant prostate cancer, renal cell carcinoma, and other solid tumor types.
  • The study concluded that cabozantinib offers a new perspective on anti-angiogenic therapy for the treatment of multiple solid tumors.
  • S. Roy, B.K. Narang, S.K. Rastogi, and R.K. Rawal, researchers from the College of Pharmacy, contributed to the study.
  • The research was published in the journal Anti-cancer Agents In Medicinal Chemistry, vol. 15, no. 1, 2014.

Statistics:

  • 2012: Cabozantinib (XL184) was approved by the US FDA on November 29 for the treatment of Medullary Thyroid Cancer (MTC).
  • 2014: The research on cabozantinib was published in the journal Anti-cancer Agents In Medicinal Chemistry (vol. 15, no. 1, 2014).
  • 37-47: The page numbers of the research article in the journal Anti-cancer Agents In Medicinal Chemistry, vol. 15, no. 1, 2014.
  • Multiple tyrosine-kinase targeted agents: Cabozantinib is a type of agent that targets multiple tyrosine kinases involved in tumor growth and angiogenesis.

Sources:

  • "A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib." Anti-cancer Agents In Medicinal Chemistry, 2014;15(1):37-47. (Bentham Science Publishers - www.benthamscience.com; Anti-cancer Agents In Medicinal Chemistry - www.benthamscience.com/cmcaca/index.htm)
  • S. Roy, Dept. of Pharmaceutical Chemistry, Indo-Soviet Friendship College of Pharmacy, Ferozepur Road, Ghal Kalan, Moga-142 001, Punjab, India.